Jennifer Schulze (Jennifer Harre)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 5

Top Topics

Pseudomonas Aeruginosa

Mesenchymal Stem Cells

Endoplasmic Reticulum Stress

Top Venues

Journal of molecular medicine (Berlin, Germany)

This page only lists publications with an associated author ORCID identifier.

Publications

Larissa Nassauer, Juliane W Schott, Jennifer Schulze, Athanasia Warnecke, Michael Morgan, Melanie Galla, Axel Schambach
The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells. Journal of molecular medicine (Berlin, Germany) 102 (9) (2024)
Larissa Nassauer, Juliane W Schott, Jennifer Schulze, Athanasia Warnecke, Michael Morgan, Melanie Galla, Axel Schambach
The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells. Journal of molecular medicine (Berlin, Germany) 102 (9) (2024)
Larissa Nassauer, Juliane W Schott, Jennifer Schulze, Athanasia Warnecke, Michael Morgan, Melanie Galla, Axel Schambach
The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells. Journal of molecular medicine (Berlin, Germany) (2024)
Larissa Nassauer, Juliane W Schott, Jennifer Schulze, Athanasia Warnecke, Michael Morgan, Melanie Galla, Axel Schambach
The caspase-inhibitor Emricasan efficiently counteracts cisplatin- and neomycin-induced cytotoxicity in cochlear cells. Journal of molecular medicine (Berlin, Germany) 102 (9) (2024)
Jennifer Schulze, Odett Kaiser, Gerrit Paasche, Hans Lamm, Andreas Pich, Andrea Hoffmann, Thomas Lenarz, Athanasia Warnecke
Effect of hyperbaric oxygen on BDNF-release and neuroprotection: Investigations with human mesenchymal stem cells and genetically modified NIH3T3 fibroblasts as putative cell therapeutics. PloS one 12 (5) (2017)